Tsuchiura Kyodo Hospital
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ewald, Gregory A
REBIRTH, NCT05180773: Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Recruiting
4
250
US
Bromocriptine, Parlodel, Cycloset, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Xarelto, Second Placebo
Dennis M. McNamara, MD, MS, National Heart, Lung, and Blood Institute (NHLBI)
Peripartum Cardiomyopathy, Postpartum
06/26
12/28
SmartHF, NCT05858320: The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients

Recruiting
3
225
US
SmartHF application
University of Michigan, Washington University, Barns Jewish Hospital, St. Louis, MO, Henry Ford Hospital, Detroit, MI, Emory University, Grady Hospital, Atlanta, GA
Heart Failure
06/26
06/26
MUSIC-HFrEF1, NCT04703842: Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Recruiting
1/2
57
US
SRD-001, Placebo
Sardocor Corp., Covance
Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
12/25
12/28
NCT04840914: A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Completed
1
44
Japan, US
LY3461767, Placebo
Eli Lilly and Company
Chronic Heart Failure With Reduced Ejection Fraction
05/24
05/24
Kakuta, Tsunekazu
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
EMPA-AHF, NCT05392764: Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Recruiting
3
524
Japan
Empagliflozin 10 MG, Placebo
Juntendo University, Boehringer Ingelheim
Acute Heart Failure
03/25
12/27
NCT04840914: A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Completed
1
44
Japan, US
LY3461767, Placebo
Eli Lilly and Company
Chronic Heart Failure With Reduced Ejection Fraction
05/24
05/24
POST-PCI FLOW, NCT04684043: Prognostic Implications of Physiologic Investigation After Revascularization With Stent

Recruiting
N/A
5100
RoW
Percutaneous coronary intervention
Bon-Kwon Koo, Inje University Ilsan Paik Hospital, Goyang, South Korea, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Tsuchiura Kyodo General Hospital, Ibaraki, Japan, McGovern Medical School at UTHealth and Memorial Hermann Hospital, TX, USA, Nagoya City University Graduate School of Medical Science, Nagoya, Japan, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium, San Raffaele Scientific Institute, Milan, Italy, Ajou University Hospital, Suwon, South Korea, University of Cincinnati, Cincinnati, OH, USA, Kyoto Second Red Cross Hospital, Kyoto, Japan, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
Coronary Disease
02/21
02/21
JDEPTH-LM, NCT06436092: Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease ( Registry)

Recruiting
N/A
280
Japan
TCROSS Co., Ltd., Kaneka Corporation
Stable Angina, Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
05/27
12/29
NCT04523194: Massachusetts General Hospital and Tsuchiura Kyodo General Hospital Coronary Imaging Collaboration

Recruiting
N/A
1000
Japan, US
Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)
Massachusetts General Hospital, Tsuchiura Kyodo General Hospital
Atherosclerosis
12/25
12/25

Download Options